CORE--CLINICAL RESEARCH AND PATIENT CARE

核心——临床研究和患者护理

• 批准号: 6109526
• 负责人: William C. Mentzer
• 金额: $ 23.29万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6109526
• 关键词: biomedical facility; blood disorder chemotherapy; bone marrow transplantation; cerebral ischemia /hypoxia; hematopoietic tissue transplantation; human subject; human therapy evaluation; hydroxyurea; longitudinal human study; magnetic resonance imaging; medical complication; patient care; positron emission tomography; sickle cell anemia; sickling inhibitor

The clinical research and patient care core programs for the Northern California Comprehensive Sickle Cell Center (NCCSCC) application are based in the East Bay at Children's Hospital and Highland Hospital Oakland, and in the West Bay at San Francisco, General Hospital/University of California, San Francisco. The large patient population enrolled in these cooperative clinical programs provides an ideal source to conduct clinical and basic research projects as proposed. Since 1978, the multi- disciplinary staff of our center has met on a regular basis to discuss patient management issues, evaluate ongoing clinical and basic research projects, and plan new research. The success of these interactions is reflected in our publications related to basic and clinical research on sickle cell disease (listed in the summary progress report), in our participation in national efforts to establish treatment guidelines for patients with sickle cell disease and in our contribution to understanding the etiology and mechanism of sickle cell clinical complications. This application describes a number of new clinical research projects: 1) anti- sickling agents including hydroxyurea-sodium phenylbutyrate, magnesium therapy, clotrimazole; 2) Deferiprone (L1) therapy; 3) CNS ischemia; 4) bone marrow transplant in the treatment of sickle cell disease; 5) core blood transplant and the development of a minority cord blood donor program. In addition the above project, the core will proved necessary samples for many basic research projects. In summary, the strength of the clinical core in our center application will enable us to complete successfully the proposed clinical research projects, participate in basic research and improve the understanding of the etiology and treatment of many sickle cell complications.

北方的临床研究和患者护理核心项目 加州综合镰状细胞中心 (NCCSCC) 申请基于 东湾儿童医院和奥克兰高地医院，以及 旧金山西湾综合医院/大学 加利福尼亚州、旧金山。大量患者入组这些项目 合作临床项目提供了进行临床的理想来源 和拟议的基础研究项目。自 1978 年以来，多 我中心纪律人员定期开会讨论 患者管理问题，评估正在进行的临床和基础研究 项目，并计划新的研究。这些互动的成功在于 反映在我们与基础和临床研究相关的出版物中 镰状细胞病（在进度总结报告中列出），在我们的 参与制定治疗指南的国家努力 镰状细胞病患者以及我们对理解的贡献 镰状细胞病临床并发症的病因和机制。这 申请描述了一些新的临床研究项目：1）抗- 镰刀剂，包括羟基脲苯丁酸钠、镁 治疗，克霉唑； 2）去铁酮（L1）治疗； 3）中枢神经系统缺血； 4） 骨髓移植治疗镰状细胞病； 5）核心 血液移植和少数脐带血捐献者的发展 程序。除了上述项目之外，核心将被证明是必要的 许多基础研究项目的样本。总结一下，实力 我们中心应用程序的临床核心将使我们能够完成 成功提出临床研究项目，参与基础研究 研究并提高对病因和治疗的认识 许多镰状细胞并发症。